I have no conflicts of interest to disclose. 2 1 10/8/2018 it will - - PDF document

i have no conflicts of interest to disclose
SMART_READER_LITE
LIVE PREVIEW

I have no conflicts of interest to disclose. 2 1 10/8/2018 it will - - PDF document

10/8/2018 Simultaneous Heart Liver Transplant for the Treatment of Decompensated Fontan Patients Seth Hollander, MD Clinical Associate Professor, Pediatrics (Cardiology) Medical Director, Cardiac Transplantation I have no conflicts of interest


slide-1
SLIDE 1

10/8/2018 1

Simultaneous Heart‐Liver Transplant for the Treatment of Decompensated Fontan Patients

Seth Hollander, MD Clinical Associate Professor, Pediatrics (Cardiology) Medical Director, Cardiac Transplantation

2

I have no conflicts of interest to disclose.

slide-2
SLIDE 2

10/8/2018 2

4

…it will

slide-3
SLIDE 3

10/8/2018 3

5 6

The Results of our “Success”

90% repaired CHD will survive into adulthood Mechanisms heart failure are different than for non CHD adults. Medical therapy often fails…Increase in referrals for transplantation 3.3% of adult heart transplants (40% increase over previous decades)

slide-4
SLIDE 4

10/8/2018 4

7

Hypoplastic Left Heart Syndrome

8

Overview

What is the Fontan Operation? Why does the liver “fail” in patients with Fontan circulation? Heart‐Liver Transplant Surgery Outcomes Immunologic Tolerance Ethics

slide-5
SLIDE 5

10/8/2018 5

9

The Fontan Operation for HLHS

10

Fontan Operation

Now standard of care for single ventricle disease. Early mortality is low. Survivors entering 20’s and 30’s. Not a long‐term solution.

slide-6
SLIDE 6

10/8/2018 6

11

History

Historically considered a contraindication to heart transplant secondary to concerns regarding bleeding, infection, varices. Liver failure in the setting of heart disease is increasing owing to improved long‐term survival in patients with single ventricle disease. Historical Contraindications = Current Indications

12

High Central Venous Pressure Decreased Cardiac Output

slide-7
SLIDE 7

10/8/2018 7

13 14

Ghaferi A, 2004 Rychik, 2013.

slide-8
SLIDE 8

10/8/2018 8

15 16

Indications

slide-9
SLIDE 9

10/8/2018 9

17

Heart‐Liver Transplantation

18

Multi‐Organ Transplantation

slide-10
SLIDE 10

10/8/2018 10

19 20

419 Heart Transplants since 1977 7 Heart‐Liver Transplants Multi‐Disciplinary Team

slide-11
SLIDE 11

10/8/2018 11

21

Our First 7 Cases

7 Patients (5 Girls, 2 Boys) Ages 12‐19 6 Single Ventricles with FALD, 2 with PLE One TOF (2 ventricle) with primary liver disease

22

Heart‐Liver Transplant Planning

Close collaboration between heart and liver teams Standardized multidisciplinary work‐up.

Ultrasound, CT, MRI Cardiac Catheterization/Hepatic Vein Wedge Pressure Gradient Consider liver biopsy (during cath)

slide-12
SLIDE 12

10/8/2018 12

23

Elastography

24

slide-13
SLIDE 13

10/8/2018 13

25

Surgical Technique

  • Historically, the heart went in first, followed

by the liver.

  • Simultaneous implantation
  • En bloc technique, where the heart and the

liver are not separated.

26

slide-14
SLIDE 14

10/8/2018 14

27

The Fontan Syndrome

28

En bloc technique

Hill AL et al, 2012 Waitlist time: 131 Days (50-622) CPB: 3.58 Hours (2.97- 4.15) Donor Ischemic Time: 4.13 Hours (3.78-6.6) Total OR Time: (13-18.65)

10 20 30 40 50 60 70 Patient 1 Patient 2 Patient 3 Patient 4 Patient 5

POST CPB ICU (48 Hrs)

slide-15
SLIDE 15

10/8/2018 15

29

Transfusions in the OR

MEAN MEDIAN RANGE pRBC (units) 22.2 (±10.3) 19 14-40 FFP (units) 17.6(± 15.3) 10 5-42 Platelets (units) 4 (± 3.5) 3 1-10 Cryoprecipitate (10 pack unit) 2.2 (± 1.3) 2 1-4

1-3 x Estimated blood volume

30

How do they do?

7 Patients 15,727 Follow Up Days 2 patients > 10 Years (Up to12 Years) About 100 Endomyocardial Biopsies

slide-16
SLIDE 16

10/8/2018 16

31

Where are they now?

All are alive and well Normal Cardiac and Liver Function 3 Transitioned to adult programs

But most impressively….

32

100

1A 1B 2 3A 3B

Rejection Grade # of Biopsies

Rejection Rates

Survival Rates 1 year ‐ > 80% National (100% at LPCH) 10 year > 70% National (100% at LPCH)

slide-17
SLIDE 17

10/8/2018 17

33

More immunosuppression? More surveillance? More biopsies?

Why do they do so well?

34

Why do they do so well?

slide-18
SLIDE 18

10/8/2018 18

35

Immunologic Tolerance

Liver protects companion organ in many combinations. Reduced rejection of both organs. Reduced incidence of coronary vascular disease Need for less immunosuppression.

36

Immunologic Tolerance

slide-19
SLIDE 19

10/8/2018 19

37 38

UNOS Final Rule

The goal of The organ allocation system in the US is to prioritize patients with the greatest medical urgency while at the same time maximizing the overall societal benefit from a limited pool of organs. Also takes into account the change in quality of life, duration of benefit, and amount

  • f resources required for successful treatment.
slide-20
SLIDE 20

10/8/2018 20

39

Our obligation as stewards…

To prioritize patients with the greatest medical urgency … jumping the line for the 2nd organ? …at the same time maximizing the overall societal benefit from a limited pool of

  • rgans.

… saving one life instead of 2? Also takes into account the change in quality of life, duration of benefit, and amount of resources required for successful treatment.

40

Commitment to Patient vs. Society

Individual Patient Advocacy Greater Good

slide-21
SLIDE 21

10/8/2018 21

41

Justice Utility

42

Conclusions

Heart‐Liver Transplant is increasing in frequency in adults and children Adolescents and adults with congenital heart disease make up a significant proportion of heart‐liver transplant candidates Indications are unclear Heavy surgical burden but patients survive Long‐term prognosis is excellent

slide-22
SLIDE 22

10/8/2018 22

43